Keyword: AstraZeneca

Patients using copay coupons were more likely to stay on their drugs longer, but the vouchers didn't help with outcomes, a new study found.

AstraZeneca said the move is meant to "consolidate the biologics manufacturing network" at one large site in Maryland.

Pharma, payers, the Trump administration and Congress all have ideas for tackling drug prices, but the trick is making those ideas work together.

With key commercial cog Mark Mallon bound for Ironwood’s CEO spot, AstraZeneca is reorganizing into two new R&D and commercial lineups.

The first week of 2019 looks a lot like 2018 in at least one regard: A Big Pharma company’s commercial head is on the move.

England's cost watchdog has removed a previous restriction on AZ's Fasenra, allowing it to be funded for an expanded pool of patients.

The year may be winding down, but AZ and Merck’s Lynparza sure isn’t. It picked up a new approval Wednesday and posted positive phase 3 data Thursday.

Allegations in nearly a dozen kickbacks lawsuits against top pharma companies are unfounded, the government said.

With China's large and increasing chronic kidney disease population, roxadustat could hit $1 billion in that country alone by 2025.

AstraZeneca felt the blow last month when key trial Mystic failed. But now that the dust has settled, it's looking for bright spots in the miss.